Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Anemia — Chronic Kidney Disease (May 2020)

Posted by Matt Breese on May 8, 2020

Find me on:

According to our recent payer coverage analysis for anemia treatments due to chronic kidney disease, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for anemia treatments due to chronic kidney disease shows that under the pharmacy benefit, about 55% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Anemia Chronic Kidney Disease-2Q2020Data snapshot as of Q2 2020

Trends: In November 2019, AstraZeneca said its FibroGen-partnered drug roxadustat, an oral first-in-class drug to treat anemia in patients with chronic kidney disease, demonstrated positive results in its Phase III trial.  

To read the full Reality Check on Anemia treatments due to Chronic Kidney Disease with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing